Clinical Study
Recombinant Human Thrombopoietin Treatment Promotes Hematopoiesis Recovery in Patients with Severe Aplastic Anemia Receiving Immunosuppressive Therapy
Table 2
Hematological response to patients treated with and without rhTPO.
| Time | Response | Patients with rhTPO, number (%) | Patients without rhTPO, number (%) | value |
| At 3 months | Total | 17 (42.5%) | 11 (22.9%) | 0.0665 | CR | 3 (7.5%) | 1 (2.1%) | PR | 14 (35%) | 10 (20.8) |
| At 6 months | Total | 25 (62.5%) | 20 (41.6%) | 0.0579 | CR | 8 (20%) | 5 (10.4%) | PR | 17 (42.5%) | 15 (31.2%) |
| At 9 months | Total | 27 (67.5%) | 23 (47.9%) | 0.0847 | CR | 10 (25%) | 7 (14.6%) | PR | 17 (42.5%) | 16 (33.3%) |
|
|
CR: complete response; PR: partial response.
|